picoplatin
Small moleculeexperimental
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals for the treatment of patients with solid tumors. — Wikipedia
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2000 (NCT00016172)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Gastrointestinal Neoplasms · Phase 1
- Head and Neck Neoplasms · Phase 1
- Intestinal Neoplasms · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 3
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
- Mol. weight
- 376.14 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPicoplatin ↗
- ChEMBLCHEMBL3544907 ↗
Also known as
- amd473
- amd 473
- amd-473
- amd-473
- amd-473
- amminedichloro(2-methylpyridine)platinum(ii)
- cis-amminedichloro(2-methylpyridine)platinum(ii)
- jm473
- jm-473
- nx-473
- nx-473
- picoplatin
- picoplatin
- picoplatin
- picoplatin
- picoplatin
- (sp-4-3)-amminedichloro(2-methylpyridine)platinium
- (sp-4-3)-amminedichloro(2-methylpyridine)platinium
- zd0473
- zd 0473
- zd-0473
- zd-0473
- zd-0473
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00710697 | Phase 1 | Jun 1, 2008 | Poniard Pharmaceuticals |
| NCT00465491 | Phase 3 | Apr 1, 2007 | Poniard Pharmaceuticals |
| NCT00465725 | Phase 1 | Apr 1, 2007 | Poniard Pharmaceuticals |
| NCT00448734 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2006 | Poniard Pharmaceuticals |
| NCT00478946 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2006 | Poniard Pharmaceuticals |
| NCT00116610 | Phase 2 | Jun 1, 2005 | Poniard Pharmaceuticals |
| NCT00021008 | Phase 2 | Jul 11, 2001 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT00016172 | Phase 1 | Nov 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Poniard Pharmaceuticals | For profit | 6 | 6 | 3 | 2005 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2000 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2001 |
4 organizations
Page 1 / 1